3.Xavier Montalban et al. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.NEJM(2019). 4.Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up to ...
[2]Le H Hua, Efficacy and Safety of Fenebrutinib, a Noncovalent, Reversible BTK Inhibitor, in MS: Primary Results of a Phase II Trial. 2023EAN. [3]Garg N, Padron EJ, Rammohan KW, Goodman CF.J Clin Med. 2022 Oct 18;11(20):6139. [4]Satterthwaite AB, et al. Semin Immunol 1998;...
1.FDA Partially Halts Sanofi's BTK Inhibitor for Multiple Sclerosis, Myasthenia Gravis 2.新浪医药《BTK抑制剂风头正盛!5款已上市产品结构有何不同?谁更具优势?》 3.一度医药《赛诺菲BTK抑制剂rilzabrutinib三期天疱疮试验失败》
BTK inhibitionTYROSINE KINASE INHIBITORCEREBROSPINAL-FLUIDCUPRIZONE MODELDEMYELINATIONEXPRESSIONLESIONSIn multiple sclerosis (MS), persisting disability can occur independent of relapse activity or development of new central nervous system (CNS) inflammatory lesions, termed chronic progression. This process occurs...
http://www.news.sanofi.us/2020-04-23-Sanofi-brain-penetrant-BTK-inhibitor-significantly-reduced-disease-activity-in-Phase-2-trial-in-relapsing-multiple-sclerosis; https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Hom...
BTK是一种常见的血液瘤靶点,目前全球已上市的6款药物在血液瘤领域获得巨大的成功,最早上市的伊布替尼曾在2021年达到97.8亿美元销售额峰值,然而由于专利到期以及其它BTK抑制剂的竞争没能挺进百亿美元大军。 鉴于BTK抑制剂在血液瘤中的竞争已经非常激烈,许多药企对BTK抑制剂进行差异化开发,探索其在慢性自发性荨麻疹(CSU...
[1] Late-breaking data for Roche’s BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis. Retrieved October 13, 2023, from https://www.roche.com/media/releases/med-cor-2023-10-13...
BTK inhibitor significantly reduced disease activity in Phase 2 trial in relapsing multiple sclerosis . Retrieved 2020-04-23, from http://www.news.sanofi.us/2020-04-23-Sanofi-brain-penetrant-BTK-inhibitor-significantly-reduced-disease-activity-in-Phase-2-trial-in-relapsing-multiple-sclerosis...
BTK inhibitor significantly reduced disease activity in Phase 2 trial in relapsing multiple sclerosis . Retrieved 2020-04-23, from http://www.news.sanofi.us/2020-04-23-Sanofi-brain-penetrant-BTK-inhibitor-significantly-reduced-disease-activity-in-Phase-2-trial-in-relapsing-multiple-sclerosis...
图片来源:《Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial》 在2022年2月举行的美洲多发性硬化症治疗和研究委员会(ACTRIMS)论坛上,赛诺菲公布的一项2b期临床试验(NCT03889639)的长期...